349
Participants
Start Date
July 31, 2006
Primary Completion Date
November 30, 2007
Study Completion Date
June 30, 2008
Vyvanse (lisdexamfetamine dimesylate), NRP104
NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
VA New York Harbor Healthcare System, New York
CNS Research Institute, P.C., Philadelphia
NeuroScience, Inc., Herndon
Marc Hertzman, MD, Rockville
Johns Hopkins at Green Spring Station, Lutherville
Psychiatric Alliance of the Blue Ridge Clinical Research, Charlottesville
Brighton Research Group, Virginia Beach
Richard Weisler and Associates, Raleigh
Duke University ADHD Program, Durham
Northwest Behavioral Research Center, Roswell
Carman Research, Smyrna
Clinical Neuroscience Solutions, Inc., Orlando
Miami Research Associates, Miami
Janus Center for Psychiatric Research LLC, West Palm Beach
Meridien Research, Tampa
Gulfcoast Clinical Research Center, Fort Myers
The Ohio State University, Columbus
Rochester Center for Behavioral Medicine, Rochester Hills
Summit Research Network (Michigan) Inc., Flint
St Charles Psychiatric Associates-Midwest Research, Saint Charles
Psychiatric Associates, Overland Park
Vince and Associates Clinical Research, Overland Park
Clinical Study Centers, LLC, Little Rock
IPS Research Company, Oklahoma City
Bayou City Research, Houston
Red Oak Psychiatry Associates, P.A., Houston
Claghorn-Lesem Research Clinic, Bellaire
R/D Clinical Research, Inc., Lake Jackson
FutureSearch Trials, Austin
John M. Turnbow, MD, PA, Lubbock
Alpine Clinical Research Center, Boulder
Center for Psychiatry and Behavioral Medicine, Las Vegas
Peninsula Research Associates, Rolling Hills Estate
Encompass Clinical Research, Spring Valley
Valley Clinical Research, Inc., El Centro
University of California, Irvine Child Development Center, Irvine
University of California, San Francisco, Dept. of Psychiatry, San Francisco
Bay Area Research Institute, Lafayette
Summit Research Network LLC (Seattle), Seattle
Psychiatric Medicine Center, New London
Masschusetts General Hospital, Cambridge
CNS Research Institute (CRI), Clementon
Oregon Center for Clinical Investigations, Inc., Portland
The Clinical Study Center, Burlington
Neuropsychiatric Associates, Woodstock
Lead Sponsor
Collaborators (1)
Shire
INDUSTRY
New River Pharmaceuticals
INDUSTRY